Central precocious puberty: Treatment with triptorelin 11.25mg

Elena Chiocca, Eleonora Dati, Giampiero I. Baroncelli, Alessandra Cassio, Malgorzata Wasniewska, Fiorella Galluzzi, Silvia Einaudi, Marco Cappa, Gianni Russo, Silvano Bertelloni

Research output: Contribution to journalArticlepeer-review


Background. Few data are available on quarterly 11.25mg GnRH analog treatment in central precocious puberty (CPP). Aim. To assess the efficacy of triptorelin 11.25mg in children with CPP. Patients. 17 patients (16 females) with CPP (7.9±0.9 years) were treated with triptorelin 11.25mg/90 days. Methods. Gonadotropins, basal-, and GnRH-stimulated peak, gonadal steroids, and pubertal signs were assessed at preinclusion and at inclusion visit, 3 months, 6 months, and 12 months of treatment. Results. At 3, 6, and 12 months, all patients had suppressed LH peak (

Original languageEnglish
Article number583751
Publication statusPublished - 2012

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Environmental Science(all)
  • Medicine(all)


Dive into the research topics of 'Central precocious puberty: Treatment with triptorelin 11.25mg'. Together they form a unique fingerprint.

Cite this